Drug Trial Radar · NCT07150546
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 14, 2025
Primary completion
Sep 30, 2026
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Sep 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial tests the safety and effectiveness of stereotactic body radiation therapy (SBRT) followed by 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in treating patients with large well-differentiated grade 1-2 digestive system neuroendocrine tumors that cannot be removed by surgery (unresectable). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. 177Lu-DOTATATE is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. 177Lu-DOTATATE builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving PRRT after SBRT may reduce the chances of the disease returning or getting worse, compared to the standard treatment of PRRT alone.
Conditions
- Digestive System Neuroendocrine Tumor
- Unresectable Digestive System Neuroendocrine Neoplasm
- Unresectable Digestive System Neuroendocrine Tumor G1
- Unresectable Digestive System Neuroendocrine Tumor G2
Interventions
Stereotactic Body Radiation TherapyRadiation
Undergo SBRT
Lutetium Lu 177 DotatateDrug
Given IV
Computed TomographyProcedure
Undergo CT and PET/CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Gallium Ga 68-DOTATATERadiation
Undergo gallium Ga 68-DOTATATE PET/CT
Positron Emission TomographyProcedure
Undergo PET/CT
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Acute Grade 3+ Non-Hematologic Adverse EventsTime frame: Within 3 months of therapy
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Emory University Hospital
Atlanta, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.